Showing results (521-530 of 585) with videos related to
Sort By:
Pageof 59
Journal of Gastroenterology and Hepatology|May 26, 2023
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2022
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practiceTakaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, et al.Cancer Medicine|October 13, 2022
Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Oncology|September 14, 2022
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 12, 2023
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumabAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Alimentary Pharmacology & Therapeutics|September 5, 2024
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patientsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Journal of Gastroenterology|August 1, 2023
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varicesFujimasa Tada, Atsushi Hiraoka, Toshifumi Tada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 10, 2021
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progressionAtsushi Hiraoka, Takashi Kumada, Takeshi Hatanaka, et al.Alimentary Pharmacology & Therapeutics|May 8, 2024
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trialToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Cancer Medicine|January 22, 2025
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular CarcinomaAtsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, et al.Pageof 59